Latest News
Timely, factual reporting across artificial intelligence, cybersecurity, companies and markets, EU AI regulation, health and biotech, and climate and energy.
Lite News is a news feed and wire service for publishers and platforms. Below is a live sample of our continuously updated reporting. Learn more about accessing and reusing our reporting | Get News Feeds
-
CoreWeave Sets 2026 Revenue Outlook at $13–$13.3 Billion
CoreWeave reported $3.661 billion in third-quarter revenue, up from $1.365 billion a year earlier.
-
OpenAI Introduces Businesses in ChatGPT Beta
Initial Business Agent access is limited to eligible U.S. e-commerce and online-service businesses, OpenAI said.
-
SAP Releases Fixes for Critical ICM2SHELL Flaws
Onapsis reported no observed in-the-wild exploitation as of November 10, 2026.
-
RWE and KKR Commit to £12 Billion Vanguard Wind Projects
RWE says offshore construction is planned to begin in early 2027, with both farms expected to be fully commissioned in 2030.
-
Anthropic Proposes IPO at $70–$78 a Share
The proposed sale includes 801.4 million new shares and 23.6 million shares from existing shareholders.
-
Microsoft Study Details Lazarus AI Agent Backdoor
Microsoft says the altered agent can produce a command only when a trigger appears in its context; execution depends on its available tools and permissions.
-
Active Exploitation Reported for OpenSSH SSHole Flaw
The flaw affects Linux systems using musl without PAM under specific password-authentication and account conditions.
-
Anthropic Launches Roadshow for Proposed IPO
The proposed offering includes 825 million Class A shares, with an estimated price range of $70 to $78 per share.
-
Microsoft Patches Outlook Flaw Cited in Active Attacks
Exploitation requires a user to open a specially prepared message file; Outlook may then contact an attacker-controlled network destination without its usual warning.
-
FDA Approves Sunharbo for Stroke Risk Reduction
In a phase 3 trial of 12,327 adults, ischemic stroke occurred in 6.2% of Sunharbo recipients and 8.4% of placebo recipients.